Takeda Pharmaceutical Shares Slump After It Books 2Q Loss, Cuts Profit Guidance
By Kosaku Narioka
Takeda Pharmaceutical shares fell sharply after it reported a second-quarter net loss due to impairments on certain products and cut its fiscal-year net-profit forecast.
The company's shares were recently 7.2% lower at 4,033 yen after falling as much as 8.2% earlier Friday morning.
Takeda said Thursday after market close that it booked net loss of Y48.0 billion ($319.2 million) for the three months ended Sept. 30. That compared with the estimated net profit of Y70.41 billion in a poll of analysts by Quick and net profit of Y61.7 billion in the year-earlier period.
The Japanese drugmaker recorded impairment losses for Alofisel, a stem-cell therapy for Crohn's disease, and lung-cancer drug Exkivity, following unfavorable trial outcomes.
As a result, the company lowered its profit forecast for the fiscal year ending March 2024, projecting that net profit would drop 71% to Y93.00 billion, down from Y142.00 billion previously forecast.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
October 26, 2023 21:24 ET (01:24 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing